This study is in progress, not accepting new patients
The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Lipella Pharmaceuticals, Inc.
- ID
- NCT03129126
- Phase
- Phase 2 Hemorrhagic Cystitis Research Study
- Study Type
- Interventional
- Participants
- About 13 people participating
- Last Updated